Mergers and Acquisitions
Subscribe to Mergers and Acquisitions

The Lead

Merck Acquires OncoEthix for $110M

December 18, 2014 8:05 am | News | Comments

Merck has acquired, through a subsidiary, OncoEthix, a Swiss-based privately held biotechnology company specializing in oncology drug development. Through the acquisition, Merck has gained an investigational, novel oral BET inhibitor, OTX015, which is currently in Phase 1b studies for the treatment of hematological malignancies and advanced solid tumors.

PwC: “Perfect Storm” for Corporate Dealmaking Drives M&A Value to Highest Level Since 2007

December 15, 2014 12:10 pm | News | Comments

A wave of corporate mega deal activity drove a significant uptick in M&A value in 2014,...

Walgreens President and CEO to Retire Following Merger with Alliance Boots

December 10, 2014 4:21 pm | News | Comments

Walgreens announced that Greg Wasson, president and chief executive officer, has informed the...

Cubist Patent Losses Won't Deter Merck

December 9, 2014 10:03 am | by The Associated Press | News | Comments

Merck remains committed to its $8.4 billion acquisition of Cubist Pharmaceuticals even though a...

View Sample

FREE Email Newsletter

Fitch: Debt-Financed M&A Stressing US Pharma Credit Profiles

December 8, 2014 3:32 pm | News | Comments

The debt-financed acquisition of Cubist Pharmaceuticals by Merck for $9.5 billion is the latest in a string of large, debt-financed acquisitions that are stressing the credit profiles of US healthcare companies, according to Fitch Ratings.  

Natrol Completes Sale to Aurobindo Pharma USA

December 8, 2014 2:00 pm | News | Comments

Natrol has announced the completion of the sale of substantially all of the company’s assets to Aurobindo Pharma USA Inc., a manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, for a purchase price of $132.5M plus assumed liabilities.

Sigma-Aldrich Stockholders Approve Acquisition by Merck KGaA

December 8, 2014 8:50 am | News | Comments

Sigma-Aldrich Corporation stockholders voted to adopt the previously announced merger agreement providing for the acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany at a special meeting of stockholders.       


Merck Buys Cubist Pharmaceuticals for $8.4B

December 8, 2014 7:53 am | News | Comments

Merck is buying Cubist Pharmaceuticals for $8.4 billion, illustrating a new emphasis on combating so-called "superbugs" that are drawing dire warnings from global health organizations.           

Noble Life Sciences Acquires Spring Valley Laboratories

December 3, 2014 10:38 am | News | Comments

Noble Life Sciences, a provider of preclinical drug development services, has announced the acquisition of Spring Valley Laboratories, a full service, GLP-compliant, preclinical contract research organization for the development of drugs, vaccines, and medical devices.

KPMG Survey: M&A Reemerges as a Leading Growth Strategy Among U.S. Organizations

December 2, 2014 2:33 pm | News | Comments

According to a survey by KPMG LLP, merger and acquisition (M&A) activity is reemerging as a leading growth strategy among U.S.organizations for 2015.  Of the 738 M&A professionals, investors and advisors who participated in the survey, 82 percent anticipate that their U.S. companies or clients will initiate at least one acquisition in 2015, compared with 63 percent in 2014.

Johnson Matthey Acquires Pharmaceutical Manufacturing Capacity in Scotland, UK

December 2, 2014 11:43 am | News | Comments

Johnson Matthey, a provider of pharmaceutical services, APIs and catalyst technologies, has announced completion of an acquisition of pharmaceutical manufacturing capacity in Scotland, U.K. The 109,000 sq. meter site was acquired to meet increasing demand for custom pharmaceutical services and active ingredients utilising enhanced manufacturing capabilities.

Imprimis Pharmaceuticals Acquires PCAB-Accredited Pharmacy in California

December 2, 2014 8:31 am | News | Comments

Imprimis Pharmaceuticals has entered into a stock purchase agreement to acquire South Coast Specialty Compounding, Inc., DBA Park Compounding (Park). The acquisition of Park is expected to close on or about January 1, 2015, subject to the satisfaction of certain customary closing conditions.


Otsuka to Buy Avanir for $3.5B

December 2, 2014 7:08 am | by By The Associated Press | News | Comments

Otsuka Pharmaceutical will spend $3.5 billion in cash to buy Avanir Pharmaceuticals in a deal that expands the Japanese drugmaker's portfolio of neurologic disease treatments. Avanir shareholders will receive $17 per share, according to the agreement announced Tuesday.

Pfizer Completes Acquisition of Baxter’s Marketed Vaccines

December 1, 2014 8:15 am | News | Comments

Pfizer has completed the acquisition of Baxter International Inc.’s portfolio of marketed vaccines. The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. Pfizer also acquired a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured.

Cocrystal Pharma and RFS Pharma Merge to Create Antiviral Development Organization

November 25, 2014 11:10 am | News | Comments

Cocrystal Pharma, a biotechnology company developing novel antiviral therapeutics for human diseases, today announced the closing of its merger with RFS Pharma, a privately owned biotech company founded by renowned drug developer, Dr. Raymond Schinazi.

Health Care M&A Leads Global Deal Surge

November 24, 2014 8:35 am | by LINDA A. JOHNSON, AP Business Writer; STEVE ROTHWELL, AP Business Writer | News | Comments

In a big year for deal making, the health care industry is a standout. Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and low interest rates are also fueling the mergers and acquisitions.

BioMarin Pharma Offers $680M for Prosensa

November 24, 2014 8:10 am | News | Comments

BioMarin Pharmaceutical will pay $680 million in cash for the Dutch biotech company Prosensa in a bid to strengthen its pipeline of genetic disorder treatments.               


Apellis Pharmaceuticals to Acquire Potentia Pharmaceuticals

November 20, 2014 8:00 am | News | Comments

Apellis Pharmaceuticals has entered into an agreement to acquire Potentia Pharmaceuticals. As part of the acquisition agreement, Apellis obtained the necessary intellectual property rights to develop its complement inhibitor drug compound (APL-2) in ophthalmology and plans its first clinical trial in dry age-related macular degeneration.

GlobalData Director: Actavis Continues Consolidation March with Highly Priced Allergan Deal

November 18, 2014 8:21 am | News | Comments

According to Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, "The integration of Allergan and Forest will help grow Actavis to a $22 billion healthcare company in 2015. This is a dramatic elevation from its $8.7 billion revenues recorded in 2013, the year in which Actavis completed the $5 billion acquisition of Warner Chilcott."

Actavis to Spend $66B on Allergan

November 17, 2014 10:24 am | by TOM MURPHY, AP Business Writer | News | Comments

Actavis will pay $66 billion to buy fellow drugmaker Allergan in a deal that could finally stop a months-long takeover push from Valeant Pharmaceuticals for the Botox maker.             

Allergan Soars on Deal Reports

November 17, 2014 8:11 am | by The Associated Press | News | Comments

Shares of Allergan jumped in premarket trading Monday after several reports surfaced over the weekend that specialty drugmaker Actavis was preparing to buy the maker of Botox, which is embroiled in a takeover battle with Valeant Pharmaceuticals.

Zoetis Adopts Shareholder Rights Plan

November 14, 2014 6:11 pm | by The Associated Press | News | Comments

Zoetis Inc. said Friday that it has adopted a one-year shareholder rights plan. These plans, often known as "poison pills", are intended to fight off hostile takeovers. Zoetis said the plan would enable existing shareholders a right to buy preferred stock if a person or group acquires at least 15 percent of the company's stock and tries to buy more.

Ackman Takes Stake in Animal-Health Company Zoetis

November 13, 2014 12:09 pm | Videos | Comments

Activist investor William Ackman has taken a roughly $2 billion stake in Zoetis and could push the animal-health company to sell itself to a larger drug maker.               

Golden Gate Capital Acquires ANGUS Chemical Company

November 12, 2014 3:12 pm | News | Comments

Golden Gate Capital today announced that it has entered into a definitive agreement to acquire ANGUS Chemical Company from The Dow Chemical Company for $1.215 billion.              

Allergan Amends Company’s Bylaws Prior to Stockholder's Meeting

November 12, 2014 8:12 am | News | Comments

Allergan today announced that its Board of Directors has approved amendments to the company’s bylaws that streamline the process associated with calling a special meeting of stockholders. The Board determined to amend the bylaws after meetings with many of the Company’s major stockholders and other governance organizations to solicit their input and perspectives.

Eurofins Acquires SF Analytical Labs

November 6, 2014 2:17 pm | News | Comments

Eurofins Scientific has announced the pending acquisition of SF Analytical (SFA) Laboratories. The transaction will close at the end of November. The acquisition strengthens Eurofins' growing presence in the US, as well as expands the current base of operations in the Midwestern United States.

Perrigo to Acquire Omega Pharma

November 6, 2014 8:26 am | News | Comments

Perrigo Company and Omega have entered into a definitive agreement in which Perrigo has agreed to acquire Omega for EUR3.6 billion, or $4.5 billion, comprised of the purchase of Omega's equity for EUR2.48 billion and the assumption of EUR1.1 billion in debt.

GVK BIO to Acquire Vanta Bioscience

November 6, 2014 8:16 am | News | Comments

GVK BIO has announced the signing of a definitive agreement to acquire Vanta Bioscience, a full service preclinical GLP toxicology and safety assessment contract research organization operating out of Chennai, India.      

Allergan Deal Inches Forward with Court's Decision

November 4, 2014 6:01 pm | by The Associated Press | News | Comments

In a win for Valeant and Pershing Square, a federal judge has decided that they can vote in takeover target Allergan's upcoming shareholder meeting.  Allergan said in a statement Tuesday that it will file an emergency appeal.    

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.